Anastasia Daifotis, '82 M.D (Janssen Scientific)

Anastasia Daifotis, '82 M.D (Janssen Scientific)

Gilbert Lecture Series

Event Date/Location

October 26, 2017 -
4:00 pm to 5:00 pm
Thomas Laboratory 003


  • Picture of Dr. Anastasia Daifotis of Janssen Scientfic

    Anastasia Daifotis, '82, M.D.

    Chief Scientific Officer, North America
    Janssen Scientific Affairs

    Anastasia G. Daifotis, M.D., is the Chief Scientific Officer, Janssen North America.  Anastasia leads the Janssen Scientific Affairs Organization and the Janssen Medical and Scientific Affairs Council.

    As the leader of Janssen Scientific Affairs, Anastasia sets the medical strategy for Janssen North America and plays a key role in shaping our overall business strategy. She is responsible for accelerating the development of medical and scientific capabilities essential to winning in a value-based healthcare system, such as Real World Evidence and healthcare economics, and for pharmacovigilance, including our Medical Information and Call Center operations.  She partners closely with our R&D and Global Medical Affairs leadership on product development programs and plays an important medical role in licensing and acquisitions.  As leader of the Medical and Scientific Affairs Council for Janssen North America, Anastasia is responsible for shaping the medical and scientific vision for the region internally and representing Janssen externally on advisory and policy-making bodies across the region.

    Anastasia brings extensive scientific, medical and commercial leadership experience, spanning drug development, medical affairs, and marketing.  She was formerly with Karos Pharmaceuticals, Inc., a privately held biopharmaceutical company, where as President and Chief Executive Officer she led development efforts in pulmonary hypertension and other orphan diseases, worked with internal scientists to develop and implement company research and development strategy, oversaw operations and represented the company with investors, scientific experts and pharmaceutical industry partners.  Prior to joining Karos, Anastasia was Senior Vice President of Clinical Development at MacroGenics, Inc., where she oversaw clinical development of several novel oncologic, infectious disease and autoimmune therapies.

    Before joining MacroGenics, Anastasia had a distinguished 16-year career at Merck, where she held medical affairs, commercial and R&D leadership roles, including Vice President and General Manager, Global Human Health, Respiratory, Bone, Arthritis and Analgesia Franchise, responsible for the global strategy and P&L of one of Merck's largest franchises, and Vice President, Clinical Research Therapeutic Area, Head, Bone, Endocrine, Immunology and Analgesia. In her last position, Vice President, Global Medical Affairs, she led the organization that provided medical support and information to Merck franchises, markets, healthcare professionals and patients regarding company products and related disease areas.

    Anastasia graduated from Princeton University with an undergraduate degree in Biology and received her M.D. from Albany Medical College. She held clinical and research fellowships in Endocrinology and a Howard Hughes fellowship at the Yale University School of Medicine and Yale-New Haven Hospita




Free and open to the university community and the public.


Bonnie Bassler, Department of Molecular Biology